Epstein–Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression

References

• Castillo JJ, Beltran BE, Miranda RN, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:529–7. doi:10.1002/ajh.24370.
   PubMed Web of Science ®Google Scholar
• Wu L, Ehlin-Henriksson B, Zhou X, Zhu H, Ernberg I, Kis LL, Klein G. Epstein-Barr virus (EBV) provides survival factors to EBV(+) diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV(+) DLBCL. Immunology. 2017;152:562–573. doi:10.1111/imm.12792.
   PubMed Web of Science ®Google Scholar
• Healy JA, Dave SS. The role of EBV in the pathogenesis of diffuse large B cell Lymphoma. Curr Top Microbiol Immunol. 2015;390:315–337. doi:10.1007/978-3-319-22822-8_13.
   PubMed Web of Science ®Google Scholar
• Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz). 2008;56:77–83. doi:10.1007/s00005-008-0014-5.
   PubMed Web of Science ®Google Scholar
• Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015;6:5997. doi:10.1038/ncomms6997.
   PubMed Web of Science ®Google Scholar
• Styles CT, Bazot Q, Parker GA, White RE, Paschos K, Allday MJ. EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency. Plos Biol. 2017;15:e2001992. doi:10.1371/journal.pbio.2001992.
   PubMed Web of Science ®Google Scholar
• Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, et al. Down-regulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood. 2011;117:5907–5917. doi:10.1182/blood-2010-09-307710.
   PubMed Web of Science ®Google Scholar
• Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27:16–26. doi:10.1097/00000478-200301000-00003.
   PubMed Web of Science ®Google Scholar
• Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinctclinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124–5132. doi:10.1158/1078-0432.CCR-06-2823.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Pittaluga S, Abdullah S, Steinberg SM, Pham TA, Davies-Hill T, Xi L, Raffeld M, Jaffe ES. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015;126:863–872. doi:10.1182/blood-2015-02-630632.
   PubMed Web of Science ®Google Scholar
• Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, Hills RK, Jaffe ES. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011;117:4726–4735. doi:10.1182/blood-2010-12-323238.
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Kahl BS. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep. 2012;7:216–220. doi:10.1007/s11899-012-0127-0.
   PubMed Web of Science ®Google Scholar
• Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gosch B, Dierlamm J, Gerull H, Nollau P, Klapper W, et al. Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. Haematologica. 2016;101:e378–381. doi:10.3324/haematol.2016.141929.
   PubMed Web of Science ®Google Scholar
• Corso J, Pan, K.T., Walter, R., Doebele, C., Mohr, S., Bohnenberger, H., Ströbel, P., Lenz, C., Slabicki, M., Hüllein, J., et al. Elucidation of tonic and activated B-cell receptor signaling in Burkitt’s lymphoma provides insights into regulation of cell survival. Proc Natl Acad Sci U S A. 2016;113:5688–5693. doi:10.1073/pnas.1601053113.
   PubMed Web of Science ®Google Scholar
• Young RM, Wu T, Schmitz R, Dawood M, Xiao W, Phelan JD, Xu W, Menard L, Meffre E, Chan WCC, et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc Natl Acad Sci U S A. 2015;112:13447–13454. doi:10.1073/pnas.1514944112.
   PubMed Web of Science ®Google Scholar
• Cha S-C, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, Wu W, Ong J, Wei J, Kwak B, et al. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol. 2013;190:4887–4898. doi:10.4049/jimmunol.1300179.
   PubMed Web of Science ®Google Scholar
• Sachen KL, Strohman MJ, Singletary J, Alizadeh AA, Kattah NH, Lossos C, Mellins ED, Levy S, Levy R. Self-antigen recognition by follicular lymphoma B-cell receptors. Blood. 2012;120:4182–4190. doi:10.1182/blood-2012-05-427534.
   PubMed Web of Science ®Google Scholar
• Battle-Lopez A, Gonzalez de Villambrosia S, Nuñez J, Cagigal M-L, Montes-Moreno S, Conde E, Piris MA. Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. Expert Rev Anticancer Ther. 2016;16:411–421. doi:10.1586/14737140.2016.1149065.
   PubMed Web of Science ®Google Scholar
• Keisuke K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;33:1687–1699. doi:10.1038/s41375-019-0380-5.
   PubMed Web of Science ®Google Scholar
• Engels N, Yigit G, Emmerich CH, Czesnik D, Schild D, Wienands J. Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal. Cell Commun Signal. 2012;10:9. doi:10.1186/1478-811X-10-9.
   PubMed Web of Science ®Google Scholar
• Seremetis S, Inghirami G, Ferrero D, Newcomb E, Knowles D, Dotto G, Dalla-Favera R. Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. Science. 1989;243:660–663. doi:10.1126/science.2536954.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, Yu H, Fletcher CDM, Freeman GJ, Shipp MA, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462–3473. doi:10.1158/1078-0432.CCR-13-0855.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014;5:12189–12202. doi:10.18632/oncotarget.v5i23.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, et al. Aberrant PD-L1 expression through 3ʹ-UTR disruption in multiple cancers. Nature. 2016;534:402–406. doi:10.1038/nature18294.
   PubMed Web of Science ®Google Scholar
• Sun C, Jia Y, Wang W, Bi R, Wu L, Bai Q, Zhou X. Integrative analysis of PD‐L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B‐cell lymphoma. Histopathology. 2018;74(4):618–628. doi:10.1111/his.13765.
   Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282. doi:10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen J, McAllister S, Koganti S, Hill E, Bhaduri-McIntosh S. Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines. J Vis Exp. 2011;57:3321. doi:10.3791/3321.
   Google Scholar